Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model
Authors
Keywords
-
Journal
ANTIVIRAL RESEARCH
Volume 209, Issue -, Pages 105492
Publisher
Elsevier BV
Online
2022-12-17
DOI
10.1016/j.antiviral.2022.105492
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
- (2022) Wen Wen et al. ANNALS OF MEDICINE
- SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
- (2022) Pengfei Li et al. CELL RESEARCH
- The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant
- (2022) Dandan Tian et al. JOURNAL OF MEDICAL VIROLOGY
- Mechanisms of action of fluvoxamine for COVID-19: a historical review
- (2022) Yaeko Hashimoto et al. MOLECULAR PSYCHIATRY
- Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
- (2022) Yunlong Cao et al. NATURE
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
- (2022) Jennifer Hammond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
- (2022) Heba N. Altarawneh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach
- (2022) Rafael Dal-Ré et al. LANCET INFECTIOUS DISEASES
- A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval
- (2022) Nada A Ashour et al. Drug Design Development and Therapy
- Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies
- (2022) Takuya Tada et al. EBioMedicine
- Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model
- (2022) Kyle Rosenke et al. JCI Insight
- SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model
- (2022) Carolin M. Lieber et al. Nature Communications
- Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice
- (2022) Ju Hwan Jeong et al. ANTIVIRAL RESEARCH
- Modeling the Binding Mechanism of Remdesivir, Favilavir, and Ribavirin to SARS-CoV-2 RNA-Dependent RNA Polymerase
- (2021) Fabian Byléhn et al. ACS Central Science
- Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2
- (2021) Wendy P. Painter et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19
- (2021) Francisco J. Salguero et al. Nature Communications
- A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques
- (2021) Paul E. Harris et al. Vaccines
- Mass Critical Care Surge Response during COVID-19: Implementation of Contingency Strategies A Preliminary Report of findings from the Task Force for Mass Critical Care
- (2021) Jeffrey R. Dichter et al. CHEST
- Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
- (2021) Saye H Khoo et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model
- (2021) Rana Abdelnabi et al. JOURNAL OF INFECTIOUS DISEASES
- Molnupiravir: coding for catastrophe
- (2021) Brandon Malone et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2
- (2021) Wendy Holman et al. Trials
- Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls
- (2021) Martina Calusic et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2
- (2021) Yuanchao Xie et al. CELL RESEARCH
- Therapeutic Emergency Use Authorizations (EUAs) During Pandemics: Double-edged Swords
- (2021) Adarsh Bhimraj et al. CLINICAL INFECTIOUS DISEASES
- Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease‐2019 (COVID‐19): A systematic review and meta‐analysis
- (2021) Zhiwei Lin et al. JOURNAL OF MEDICAL VIROLOGY
- Structures and functions of coronavirus replication–transcription complexes and their relevance for SARS-CoV-2 drug design
- (2021) Brandon Malone et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
- (2021) Angélica Jayk Bernal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir overcomes the S861 roadblock in SARS-CoV-2 polymerase elongation complex
- (2021) Jiqin Wu et al. Cell Reports
- Emergency Use Authorizations of COVID-19–Related Medical Products
- (2021) Itay Moshkovits et al. JAMA Internal Medicine
- Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
- (2021) Philippine Eloy et al. EBioMedicine
- Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
- (2021) Ching-Chi Lee et al. Antibiotics-Basel
- Molnupiravir in COVID-19: A systematic review of literature
- (2021) Awadhesh Kumar Singh et al. Diabetes & Metabolic Syndrome-Clinical Research & Reviews
- Hospital Preparedness for COVID-19: A Practical Guide from a Critical Care Perspective
- (2020) Kelly M. Griffin et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Respiratory disease in rhesus macaques inoculated with SARS-CoV-2
- (2020) Vincent J. Munster et al. NATURE
- Compassionate Use of Remdesivir for Patients with Severe Covid-19
- (2020) Jonathan Grein et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 infection protects against rechallenge in rhesus macaques
- (2020) Abishek Chandrashekar et al. SCIENCE
- Lung fibrosis: an undervalued finding in COVID-19 pathological series
- (2020) Federica Grillo et al. LANCET INFECTIOUS DISEASES
- Computational studies reveal mechanism by which quinone derivatives can inhibit SARS-CoV-2. Study of embelin and two therapeutic compounds of interest, methyl prednisolone and dexamethasone
- (2020) Francesco Caruso et al. Journal of Infection and Public Health
- Healing after Covid-19: Are Survivors at Risk for Development of Pulmonary Fibrosis?
- (2020) Lindsay T McDonald AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- A review on favipiravir: the properties, function, and usefulness to treat COVID-19
- (2020) Seyed MohammadReza Hashemian et al. Expert Review of Anti-Infective Therapy
- Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
- (2020) Robert M. Cox et al. Nature Microbiology
- Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia
- (2019) Mart Toots et al. Science Translational Medicine
- Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model
- (2019) Mart Toots et al. Translational Research
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started